Cancers (Jun 2024)

<i>KRAS</i> Exon 2 Mutations in Patients with Sporadic Colorectal Cancer: Prevalence Variations in Mexican and Latin American Populations

  • José Luis Venegas-Rodríguez,
  • Jesús Arturo Hernández-Sandoval,
  • Melva Gutiérrez-Angulo,
  • José Miguel Moreno-Ortiz,
  • Anahí González-Mercado,
  • Jorge Peregrina-Sandoval,
  • Helen Haydee Fernanda Ramírez-Plascencia,
  • Beatriz Armida Flores-López,
  • Carlos Rogelio Alvizo-Rodríguez,
  • Jesús Alonso Valenzuela-Pérez,
  • Sergio Cervantes-Ortiz,
  • María de la Luz Ayala-Madrigal

DOI
https://doi.org/10.3390/cancers16132323
Journal volume & issue
Vol. 16, no. 13
p. 2323

Abstract

Read online

We searched for the prevalence of actionable somatic mutations in exon 2 of the KRAS gene in western Mexican patients with CRC. Tumor tissue DNA samples from 150 patients with sporadic CRC recruited at the Civil Hospital of Guadalajara were analyzed. Mutations in exon 2 of the KRAS gene were identified using Sanger sequencing, and the data were analyzed considering clinical–pathological characteristics. Variants in codon 12 (rs121913529 G>A, G>C, and G>T) and codon 13 (rs112445441 G>A) were detected in 26 patients (with a prevalence of 17%). No significant associations were found between these variants and clinical–pathological characteristics (p > 0.05). Furthermore, a comprehensive search was carried out in PubMed/NCBI and Google for the prevalence of KRAS exon 2 mutations in Latin American populations. The 17 studies included 12,604 CRC patients, with an overall prevalence of 30% (95% CI = 0.26–0.35), although the prevalence ranged from 13 to 43% across the different data sources. Determining the variation and frequency of KRAS alleles in CRC patients will enhance their potential to receive targeted treatments and contribute to the understanding of the genomic profile of CRC.

Keywords